<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRIMETHOPRIM <img border="0" src="../images/pr.gif"/></span><br/>(trye-meth'oh-prim)<br/><span class="topboxtradename">Primsol, </span><span class="topboxtradename">Proloprim, </span><span class="topboxtradename">Trimpex<br/></span><b>Classifications:</b> <span class="classification">antiinfective, urinary tract</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 200 mg tablets; 50 mg/5 mL liquid</p>
<h1><a name="action">Actions</a></h1>
<p>Antiinfective and folic acid antagonist with slow bactericidal action. Binding and interference with cell growth is 1000 times
         stronger in bacterial than in mammalian cells. Most pathogens causing urinary tract infection (UTI) are in normal vaginal
         and fecal flora.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against most common UTI pathogens, including <i>Escherichia coli, Enterobacter</i> sp., <i>Klebsiella pneumoniae, Proteus mirabilis,</i> most strains of <i>Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus </i>organisms (including <i>S. saprophyticus</i>). Not effective against <i>Bacteroides, Lactobacillus </i>sp., <i>Chlamydia</i> or <i>Pneumocystis carinii, Pseudomonas aeruginosa</i>. Resistant strains of <i>Enterobacteriaceae</i> (<i>E. coli</i> and <i>Klebsiella</i> and <i>Proteus</i> sp.) may develop during therapy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Initial episodes of acute uncomplicated UTIs, acute otitis media in children.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment and prophylaxis of chronic and recurrent UTI in both men and women; treatment in conjunction with dapsone of initial
         episodes of <i>Pneumocystis carinii</i> pneumonia; treatment of travelers' diarrhea.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Megaloblastic anemia secondary to folate deficiency; creatinine clearance 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Tract Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg b.i.d. or 200 mg once/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 23 mg/kg q12h times 10 d<br/><br/><span class="indicationtitle">Acute Otitis Media</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;6 mo,</i> 10 mg/kg divided q12 h times 10 d<br/><br/><span class="indicationtitle">Travelers' Diarrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with 240 mL (8 oz) of fluid if not contraindicated.</li>
<li>Store at 15°30° C (59°86° F) in dry, light-protected place.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Epigastric discomfort, nausea, vomiting, glossitis, abnormal taste sensation. <span class="typehead">Hematologic:</span> Neutropenia, <span class="speceff-common">megaloblastic anemia,</span> methemoglobinemia, leukopenia, thrombocytopenia (rare). <span class="typehead">Skin:</span>
<span class="speceff-common">Rash, pruritus</span>, <span class="speceff-life">exfoliative dermatitis</span>, photosensitivity. <span class="typehead">Body as a Whole:</span> Fever. <span class="typehead">Metabolic:</span> Increased serum transaminases (ALT, AST), bilirubin, creatinine, BUN. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Interferes with serum <span class="alt">methotrexate assays</span> that use a competitive binding protein technique with a bacterial dihydrofolate reductase as the binding protein. May cause
         falsely elevated <span class="alt">creatinine</span> values when <span class="alt">Jaffe reaction</span> is used.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May inhibit <b>phenytoin</b> metabolism causing increased levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Almost completely absorbed from GI tract. <span class="typehead">Peak:</span> 14 h. <span class="typehead">Distribution:</span> Widely distributed, including lung, saliva, middle ear fluid, bile, bone, CSF; crosses placenta; appears in breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 80% excreted in urine unchanged. <span class="typehead">Half-Life:</span> 811 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain C&amp;S tests before trimethoprim therapy is initiated; therapy may be started before results are received.
            Obtain periodic urine cultures, BUN, creatinine clearance, CBC, Hgb, and Hct. Follow-up cultures may be ordered at end of
            treatment to verify elimination of causative organism.
         </li>
<li>Reinforce necessity to adhere to established drug regimen. Recurrent infection after terminating prophylactic treatment of
            UTI may occur even after 6 mo of therapy.
         </li>
<li>Assess urinary pattern during treatment. Altered pattern (frequency, urgency, nocturia, retention, polyuria) may reflect emerging
            drug resistance, necessitating change of drug regimen. Periodically check for bladder distention.
         </li>
<li>Be alert for toxic effects on bone marrow, particularly in older adults, malnourished, alcoholic, pregnant, or debilitated
            patients. Recognize and report signs of infection or anemia.
         </li>
<li>Drug-induced rash, a common adverse effect, is usually maculopapular, pruritic, or morbilliform and appears 714 d after
            start of therapy with daily doses of 200 mg or less.
         </li>
<li>Watch for overdose symptoms: Nausea, vomiting, diarrhea, mental depression, confusion, facial swelling, elevated serum transaminases.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take all prescribed medication; uncomplicated UTIs usually respond to treatment.</li>
<li>Drink fluids liberally (20003000 mL/d, if not contraindicated) to help flush out urinary bacteria.</li>
<li>Take urinary analgesic for pain and discomfort with voiding before full drug effects are experienced. Report pain and hematuria
            to physician immediately.
         </li>
<li>Do not postpone voiding even though increases in fluid intake may cause more frequent urination.</li>
<li>Do not use douches or sprays during treatment periods; practice careful perineal hygiene to prevent reinfection.</li>
<li>Report to physician promptly any symptoms of a hematologic disorder (fever, sore throat, pallor, purpura, ecchymosis).</li>
<li>Consult physician if severe traveler's diarrhea does not respond to 35 d therapy (i.e., persistence of symptoms of severe
            nausea, abdominal pain, diarrhea with mucus or blood, and dehydration).
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>